EXICURE, INC. Net Change in Cash
EXICURE, INC. (XCUR) reported Net Change in Cash of -$2.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$1.14M.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$2.09M.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$450.00K, a 132.54% decline year-over-year.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $1.38M.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$8.76M, a 183.51% decline from fiscal 2024.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $10.49M.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$7.76M.
- EXICURE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$34.07M, a 463.11% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.03M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$1.14M 10-Q · filed 2026-05-29 | |||
| 2025-12-31 | -$8.76M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | -$8.07M 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | -$4.65M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$2.09M 10-Q · filed 2026-05-29 | |||
| 2024-12-31 | $10.49M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | -$1.06M 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | -$616.00K 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | -$450.00K 10-Q · filed 2025-06-27 | |||
| 2023-12-31 | -$7.76M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | -$7.66M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$6.24M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $1.38M 10-Q · filed 2024-06-17 | |||
| 2022-12-31 | -$34.07M 10-K · filed 2024-06-06 | |||
| 2022-09-30 | -$27.00M 10-Q · filed 2024-05-16 | |||
| 2022-06-30 | -$21.45M 10-Q/A · filed 2024-06-06 | |||
| 2022-03-31 | -$18.75M 10-Q/A · filed 2024-06-06 | |||
| 2021-12-31 | $9.38M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $18.62M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $9.32M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $1.03M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$14.00M 10-K · filed 2022-03-25 | |||
| 2020-09-30 | -$15.80M 10-Q · filed 2021-11-19 | |||
| 2020-06-30 | -$30.06M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$22.68M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $22.19M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $44.12M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$9.09M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | -$4.07M 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |